Investors anticipate a faster decline in the company's revenue, despite its history of growth. The forecasted negative growth is disappointing and is weighing down the shares. A drastic rise in stock price seems unlikely without a material change.
The company's underperformance over the past year may signal unresolved issues. Investors should prioritize high-quality businesses, even during market downturns. Future earnings will be key for current shareholders' profitability.
$Methode Electronics(MEI.US)$Methode Electronics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Dimensional Fund Advisors LP(5.4%)
With Methode Electronics' revenue performance expected to worsen, the P/S ratio remains low. Despite low P/S ratios often suggesting value, the lack of signs of improvement casts doubt on whether the P/S ratio has reached rock bottom, pointing to potential further drops in stock prices.
Despite falling EPS, the situation could've been worse. Methode Electronics' dwindling revenue, earnings, and significant insider buying send mixed signals. Further research advised for serious investors.
Methode Electronics股票讨论区
2007年上市的美国公司,主要做远程控制,电子,无线和传感器业务。
5年来营收持续增长,营业利润受毛利率下滑费占比提升影响除2020年外下滑了4年,净利润受其它非经营收入影响近3年持续大幅下滑。毛利率近5年从26.6%下降到22.4%,净资产收益率从2020年16.8%高点下降到8.3%。
2024年前3季度营收萎缩4.7%,营业利润受毛利率下滑费占比提升影响大幅萎缩92.7%,净利润受资本性资产减值影响大幅亏损0.66亿。
目前市盈率6,考虑到目前业务仍无好转迹象,暂时观望。
Most anticipated earnings and economic releases for the coming week, June 19th 23’
...
专栏Today's pre-market stock movers: HTZ, SNOW, MRNA, BP and more
• $MorphoSys(MOR.US)$ +7.9% (entered into equity participation and license agreements for felzartamab and MOR210)
• $Day One Biopharmaceuticals(DAWN.US)$ +7.4% (prices offering of 10 mln shares of common stock at $15.00 per share)
• $赫兹租车(HTZ.US)$ +6.1% (authorizes new $2.0 bln share repurchase program)
• $EverCommerce(EVCM.US)$ +3.6% (announces $50 million share repurchase program)
• $Sprinklr(CXM.US)$ +3.6% (In ...
暂无评论